Cardiff Oncology Inc


-0.47 (-4.13%)

quotes and stock data delayed 15 minutes

52 wk hi

52 wk low





Burn Rate (Qtr)


Mkt Cap


Avg Volume


*cash/burn updated:


Company Profile

At Cardiff Oncology, our mission is to turn the tide on cancer by developing onvansertib, a first-in-class, third generation Polo-like Kinase 1 (PLK1) inhibitor, to treat cancers with the greatest medical need for new therapeutic options to overcome resistance, improve response and increase overall survival.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Onvansertib (inhibitor of Polo-like Kinase 1)

Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 2


Data readout

Phase 2 Data readout TBA

Onvansertib in combination with Zytiga (abiraterone)

Prostate Cancer (Resistant Metastatic Castration-Resistant)

Phase 2

February 11-13, 2021

Data readout

February 2021: ASCO GU presentation (planned)

Onvansertib in Combination with Second-Line Standard-of-Care (PLK1)

KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

Phase 1b/2


Data readout

Presented data from the 1b segment at ASCO in early 2021. Are enrolling the phase 2 segment of approximately 26 patients.

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon